Polycythemia Differential Diagnosis in Primary Care: A Comprehensive Guide

Introduction

Polycythemia vera (PV) is a myeloproliferative neoplasm characterized by the overproduction of red blood cells, often accompanied by increased white blood cell and platelet counts. This condition, stemming from a mutation in hematopoietic progenitor cells, notably the Janus kinase-2 (JAK2) mutation, leads to increased blood viscosity and a heightened risk of thrombosis. While PV is relatively rare, primary care physicians are often the first point of contact for patients presenting with related symptoms or abnormal blood counts. Therefore, understanding the differential diagnosis of polycythemia in the primary care setting is crucial for timely and accurate diagnosis, appropriate referral, and effective management. This article aims to provide a comprehensive guide to the differential diagnosis of polycythemia, focusing on distinguishing primary PV from other conditions in primary care.

Etiology of Polycythemia Vera

The underlying cause of polycythemia vera is neoplastic proliferation within the bone marrow. This process involves a signaling defect that results in an abnormal response to growth factors. The hallmark of PV is the presence of an abnormal clonal cell line that disrupts normal hematopoietic lineage proliferation. A significant genetic factor in PV is the Janus kinase-2 (JAK2) gene mutation, found in approximately 90% of PV cases. This mutation leads to constitutive activation of cytokine signaling, driving the overproduction of blood cells. Cytogenetic abnormalities are also observed in a substantial proportion of PV patients, increasing over the disease course.

Epidemiology of Polycythemia Vera

Polycythemia vera affects individuals across all ethnic backgrounds and shows a slight male predominance. While it can occur at any age, the median age at diagnosis is around 60 years. The incidence of PV varies geographically, with lower rates reported in Japan compared to the United States and Europe. In the US, PV affects approximately 0.6 to 1.6 per million people, highlighting its relative rarity but importance in differential diagnosis, especially when considering more common causes of erythrocytosis.

Pathophysiology of Polycythemia

In polycythemia vera, the bone marrow is characterized by a mix of normal and abnormal clonal stem cells. The abnormal clones dominate, suppressing the growth and maturation of normal stem cells. This unregulated neoplastic proliferation, particularly driven by the JAK2V617F mutation, leads to panmyelosis – the overproduction of red blood cells, white blood cells, and platelets. The JAK2V617F mutation, a valine to phenylalanine substitution at position 617 of the JAK2 gene, is a key driver, causing cytokine receptors to be constitutively active. This mutation is not exclusive to PV, being present in a significant percentage of essential thrombocythemia and primary myelofibrosis cases as well, which is important to consider in the differential diagnosis of myeloproliferative neoplasms. The excessive production of blood cells, especially red blood cells, increases blood viscosity, leading to many of the clinical manifestations and complications of PV, such as thrombosis and bleeding.

Histopathological Findings in Polycythemia Vera

Histopathological findings in PV vary depending on the stage of the disease. Peripheral blood smears in pre-polycythemia and overt polycythemia typically show normochromic and normocytic red blood cells. However, iron deficiency, which can be induced by phlebotomy treatment, can lead to a hypochromic and microcytic pattern. Platelet and white blood cell counts are often elevated. Leukocytosis, predominantly neutrophilic, is common without the presence of blast cells. In the post-polycythemic stage, myelofibrosis can develop, indicated by teardrop red blood cells, poikilocytosis, and circulating nucleated red cells.

Bone marrow biopsies in PV generally reveal hypercellularity with panproliferation across all cell lines. Erythrocytosis is prominent in pre-polycythemia, with increased red cell mass in overt polycythemia. In post-polycythemia, increased reticulin deposition is seen with fibrosis, ineffective production, and extramedullary hematopoiesis. These bone marrow findings, in conjunction with clinical and molecular data, are crucial for differentiating PV from other causes of erythrocytosis.

Clinical Presentation: Recognizing Polycythemia Vera in Primary Care

Patients with polycythemia vera often present with symptoms related to hyperviscosity and thrombosis, which impair oxygen delivery. Common complaints include fatigue, headache, dizziness, tinnitus, vision changes, insomnia, claudication, pruritus, gastritis, and early satiety. Aquagenic pruritus, itching triggered by hot water exposure, is a particularly characteristic symptom, reported by up to 40% of patients. Erythromelalgia, a burning pain in hands and feet accompanied by erythema or pallor, can also occur in PV and essential thrombocythemia.

Bleeding and thrombotic events are significant complications. Bleeding can manifest as epistaxis, gum bleeding, and gastrointestinal bleeding. Thrombotic events can include deep venous thrombosis (DVT), pulmonary embolism (PE), Budd-Chiari syndrome, splanchnic vein thrombosis, stroke, and arterial thrombosis. Early satiety is often due to splenomegaly, which also contributes to abdominal discomfort. Peptic ulcer disease and gastrointestinal discomfort are common, likely due to increased histamine release and hyperviscosity affecting gastrointestinal blood supply.

Physical examination may reveal plethora and flushing of the face and palms, conjunctival injection, and skin excoriations from pruritus. Splenomegaly and hepatomegaly are frequently observed. In primary care, these signs and symptoms, especially when coupled with abnormal complete blood count (CBC) results showing elevated hemoglobin or hematocrit, should raise suspicion for PV and prompt further investigation.

Image: Facial plethora, a reddish or ruddy complexion, is a common physical finding in patients with polycythemia vera due to increased red blood cell mass and blood viscosity.

Evaluation and Diagnostic Criteria for Polycythemia Vera

The diagnosis of polycythemia vera has evolved, with the 2016 World Health Organization (WHO) criteria being the current standard. These criteria are essential for differentiating PV from other causes of erythrocytosis in primary care. The WHO criteria include major and minor criteria:

Major Criteria:

1. Elevated Hemoglobin or Hematocrit: Hemoglobin > 16.5 g/dL or hematocrit > 49% in men, or hemoglobin > 16 g/dL or hematocrit > 48% in women; or red blood cell mass > 25% above normal predicted.
2. Bone Marrow Biopsy: Hypercellular bone marrow for age with trilineage growth (panmyelosis), including prominent erythroid, granulocytic, and megakaryocytic proliferation with pleomorphic, mature megakaryocytes.
3. JAK2 V617F or JAK2 exon 12 Mutation: Presence of JAK2 mutation.

Minor Criterion:

1. Subnormal Serum Erythropoietin (EPO) Level: Serum erythropoietin level below the normal reference range.

According to the WHO diagnostic criteria, PV diagnosis requires either all three major criteria or the first two major criteria and the minor criterion to be met. It is critical to rule out secondary causes of polycythemia before applying these criteria. In primary care, initial evaluation usually involves a CBC, which may reveal elevated hemoglobin, hematocrit, and potentially increased white blood cell and platelet counts. If erythrocytosis is confirmed, further investigations, including EPO level measurement and JAK2 mutation testing, are necessary, often requiring referral to a hematologist.

Differential Diagnosis in Primary Care: Distinguishing PV from Other Conditions

The differential diagnosis of polycythemia in primary care is broad and includes both primary and secondary causes of erythrocytosis. It’s crucial to differentiate PV from these conditions to ensure appropriate management.

1. Secondary Polycythemia:

• Hypoxia-related: This is the most common cause of erythrocytosis. Conditions causing chronic hypoxia, such as chronic obstructive pulmonary disease (COPD), sleep apnea, high-altitude living, and cyanotic heart disease, stimulate erythropoietin production, leading to increased red blood cell production. In secondary polycythemia due to hypoxia, EPO levels are typically normal or elevated, unlike in PV where EPO levels are usually low or normal.
• Spurious Polycythemia (Gaisböck Syndrome or Relative Polycythemia): This condition is characterized by elevated hematocrit but normal red blood cell mass. It’s often associated with obesity, hypertension, smoking, and diuretic use. Plasma volume is reduced, leading to hemoconcentration. EPO levels are normal.
• Erythropoietin-Secreting Tumors: Certain tumors, such as renal cell carcinoma, hepatocellular carcinoma, pheochromocytoma, and cerebellar hemangioblastoma, can secrete erythropoietin, leading to secondary polycythemia. EPO levels are elevated in these cases.
• Androgen Use: Exogenous androgens can stimulate erythropoiesis and cause secondary polycythemia.

2. Primary Polycythemia (Other Myeloproliferative Neoplasms):

• Essential Thrombocythemia (ET): ET is another myeloproliferative neoplasm characterized primarily by thrombocytosis. While erythrocytosis can occur in ET, it’s not the defining feature. Distinguishing between PV and ET can be challenging, especially in early stages. JAK2, CALR, and MPL mutations are relevant in both conditions, but bone marrow morphology and predominant cell lineage proliferation help differentiate them.
• Primary Myelofibrosis (PMF): PMF is characterized by bone marrow fibrosis, splenomegaly, and leukoerythroblastosis. While erythrocytosis can occur in early stages, anemia and cytopenias are more common as the disease progresses. Bone marrow biopsy and clinical features readily distinguish PMF from PV.
• Chronic Myeloid Leukemia (CML): CML is characterized by the Philadelphia chromosome and predominantly granulocytic proliferation. While total white blood cell count is elevated in PV, the presence of the BCR-ABL1 fusion gene and the clinical presentation of CML are distinct from PV.

3. Rare Genetic Causes:

• Erythropoietin Receptor Mutations: Rare mutations in the erythropoietin receptor can cause familial erythrocytosis, mimicking PV with increased red cell mass and low EPO. However, the mechanism is an oversensitive receptor to EPO, not EPO independence as in PV.
• Hemoglobinopathies with High Oxygen Affinity: Certain hemoglobin variants with increased oxygen affinity can lead to tissue hypoxia and secondary erythrocytosis, though this is a less common cause encountered in primary care.

Diagnostic Approach in Primary Care:

1. Initial Assessment: Evaluate the patient’s history for symptoms suggestive of PV or secondary polycythemia, such as smoking history, respiratory or cardiac conditions, sleep apnea, medications (androgens, diuretics), and symptoms like pruritus, erythromelalgia, and early satiety. Perform a physical exam to assess for plethora, splenomegaly, and signs of hypoxia.

2. Complete Blood Count (CBC): The CBC is the initial screening test. Elevated hemoglobin and hematocrit are key findings. Assess white blood cell and platelet counts as well.

3. Repeat CBC and Rule Out Spurious Polycythemia: Repeat CBC to confirm erythrocytosis. Consider spurious polycythemia, especially in obese, hypertensive patients. Assess hydration status and consider repeating CBC after ensuring adequate hydration.

4. Erythropoietin (EPO) Level: Measure serum EPO level. Low or normal EPO in the presence of erythrocytosis is highly suggestive of PV or other primary polycythemias. Elevated EPO suggests secondary polycythemia.

5. Arterial Blood Gas (ABG) or Pulse Oximetry: Assess oxygen saturation to rule out hypoxia-induced secondary polycythemia. If oxygen saturation is low, further investigate for underlying pulmonary or cardiac conditions.

6. JAK2 Mutation Testing: If EPO is low or normal and secondary causes are not evident, order JAK2 V617F mutation testing. A positive JAK2 mutation strongly supports the diagnosis of PV.

7. Referral to Hematologist: Refer patients with suspected PV (based on initial workup including CBC, EPO, and JAK2 testing) to a hematologist for definitive diagnosis, bone marrow biopsy, and further management. Bone marrow biopsy is crucial for confirming panmyelosis and excluding other myeloproliferative neoplasms.

Image: A diagnostic algorithm for approaching patients with suspected polycythemia, guiding primary care physicians through initial assessments and steps towards definitive diagnosis and referral.

Treatment and Management Considerations in Primary Care

While the definitive management of polycythemia vera is overseen by hematologists, primary care physicians play a vital role in the ongoing care and management of patients with PV, particularly in managing comorbidities and recognizing complications.

Initial Management by Hematologist: Treatment goals for PV are to reduce the risk of thrombosis and manage symptoms. Phlebotomy to maintain hematocrit < 45% is the cornerstone of therapy for all PV patients. Low-dose aspirin is also typically recommended to reduce thrombotic risk, unless contraindicated. For high-risk patients (older age, history of thrombosis), cytoreductive therapy, often with hydroxyurea, is indicated.

Primary Care Role in Ongoing Management:

• Monitoring and Follow-up: After diagnosis and initial management by a hematologist, primary care physicians often participate in routine monitoring, including regular CBC checks to ensure hematocrit is within target range.
• Comorbidity Management: Manage cardiovascular risk factors such as hypertension, hyperlipidemia, diabetes, and obesity. Encourage smoking cessation.
• Symptom Management: Address symptoms such as pruritus, fatigue, and gastrointestinal discomfort. Work with the hematologist to coordinate symptom relief strategies.
• Thrombosis and Bleeding Risk Awareness: Educate patients about the signs and symptoms of thrombosis and bleeding and when to seek immediate medical attention.
• Referral for Complications: Recognize and promptly refer patients back to hematology for complications such as thrombosis, bleeding events, myelofibrosis progression, or transformation to acute leukemia.
• Vaccination and Preventative Care: Ensure patients receive appropriate vaccinations and preventative care, considering their underlying myeloproliferative neoplasm.

Prognosis and Complications

The prognosis for polycythemia vera has significantly improved with current treatments. Median survival for treated PV patients is substantial, often exceeding a decade, especially for those diagnosed at a younger age. However, PV is a chronic condition with potential for serious complications.

Major Complications:

• Thrombosis: Arterial and venous thrombosis remain the most significant causes of morbidity and mortality in PV.
• Hemorrhage: Bleeding complications, although less common than thrombosis, can occur, particularly with very high platelet counts or aspirin use.
• Myelofibrosis Transformation: Over time, PV can progress to myelofibrosis, a more aggressive phase with bone marrow scarring and cytopenias.
• Leukemic Transformation: Transformation to acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) is a severe, albeit less common, complication.

Early diagnosis, appropriate management, and close monitoring are crucial to minimize these risks and improve patient outcomes.

Enhancing Healthcare Team Outcomes

Effective management of polycythemia vera requires a collaborative interprofessional team. Primary care physicians are essential in the initial recognition and differential diagnosis of polycythemia, initiating early investigations, and coordinating referrals to hematologists. Hematologists provide specialized diagnosis, treatment planning, and ongoing management of PV. Nurses, pharmacists, and other healthcare professionals contribute to patient education, symptom management, and monitoring adherence to treatment plans. Open communication and coordinated care among all team members are vital to optimize patient outcomes and quality of life.

Conclusion

Polycythemia vera, while a rare condition, necessitates careful consideration in the differential diagnosis of erythrocytosis in primary care. Primary care physicians are at the forefront of identifying patients with potential PV based on clinical presentation and initial blood work. Understanding the differential diagnoses, initiating appropriate investigations such as EPO levels and JAK2 mutation testing, and ensuring timely referral to hematology are critical steps in the diagnostic pathway. While hematologists direct the specialized treatment of PV, primary care providers play an ongoing role in managing comorbidities, monitoring for complications, and providing comprehensive care to these patients. By working collaboratively within an interprofessional team, healthcare providers can significantly improve the outcomes and quality of life for individuals with polycythemia vera.

References

1. Barbui T, Barosi G, Birgegard G, et al. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol. 2011;29(6):761-70.
2. Anía BJ, Suman VJ, Sobell JL, Codd MB, Silverstein MN, Melton LJ. Trends in the incidence of polycythemia vera among Olmsted County, Minnesota residents, 1935-1989. Am J Hematol. 1994;47(2):89-93.
3. Berlin NI. Diagnosis and classification of the polycythemias. Semin Hematol. 1975;12(4):339-51.
4. Johansson P. Epidemiology of the myeloproliferative disorders polycythemia vera and essential thrombocythemia. Semin Thromb Hemost. 2006;32(3):171-3.
5. James C, Ugo V, Le Couédic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;434(7037):1144-8.
6. Spivak JL, Silver RT. The revised World Health Organization diagnostic criteria for polycythemia vera, essential thrombocytosis, and primary myelofibrosis: an alternative proposal. Blood. 2008;112(2):231-9.
7. Wasserman LR. The management of polycythaemia vera. Br J Haematol. 1971;21(4):371-6.
8. Lelonek E, Matusiak Ł, Wróbel T, Szepietowski JC. Aquagenic Pruritus in Polycythemia Vera: Clinical Characteristics. Acta Derm Venereol. 2018;98(5):496-500.
9. Saini KS, Patnaik MM, Tefferi A. Polycythemia vera-associated pruritus and its management. Eur J Clin Invest. 2010;40(9):828-34.
10. Tefferi A, Rumi E, Finazzi G, et al. Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. Leukemia. 2013;27(9):1874-81.
11. Michiels JJ. Erythromelalgia and vascular complications in polycythemia vera. Semin Thromb Hemost. 1997;23(5):441-54.
12. Sekhar M, McVinnie K, Burroughs AK. Splanchnic vein thrombosis in myeloproliferative neoplasms. Br J Haematol. 2013;162(6):730-47.
13. Gilbert HS, Warner RR, Wasserman LR. A study of histamine in myeloproliferative disease. Blood. 1966;28(6):795-806.
14. Accurso V, Santoro M, Raso S, et al. Splenomegaly impacts prognosis in essential thrombocythemia and polycythemia vera: A single center study. Hematol Rep. 2019;11(4):8281.
15. Streiff MB, Smith B, Spivak JL. The diagnosis and management of polycythemia vera in the era since the Polycythemia Vera Study Group: a survey of American Society of Hematology members’ practice patterns. Blood. 2002;99(4):1144-9.
16. Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391-405.
17. Tefferi A, Vannucchi AM, Barbui T. Polycythemia vera treatment algorithm 2018. Blood Cancer J. 2018;8(1):3.
18. Marchioli R, Finazzi G, Specchia G, et al. Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med. 2013;368(1):22-33.
19. van Genderen PJ, Mulder PG, Waleboer M, van de Moesdijk D, Michiels JJ. Prevention and treatment of thrombotic complications in essential thrombocythaemia: efficacy and safety of aspirin. Br J Haematol. 1997;97(1):179-84.
20. Tefferi A, Barbui T. Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management. Am J Hematol. 2015;90(2):162-73.
21. Büyükaşık Y, Ali R, Turgut M, et al. Patterns of Hydroxyurea Prescription and Use in Routine Clinical Management of Polycythemia Vera: A Multicenter Chart Review Study. Turk J Haematol. 2020;37(3):177-185.
22. Slakey DP, Klein AS, Venbrux AC, Cameron JL. Budd-Chiari syndrome: current management options. Ann Surg. 2001;233(4):522-7.
23. Tefferi A, Spivak JL. Polycythemia vera: scientific advances and current practice. Semin Hematol. 2005;42(4):206-20.
24. Arcasoy MO, Degar BA, Harris KW, Forget BG. Familial erythrocytosis associated with a short deletion in the erythropoietin receptor gene. Blood. 1997;89(12):4628-35.
25. Ruggeri M, Rodeghiero F, Tosetto A, et al. Postsurgery outcomes in patients with polycythemia vera and essential thrombocythemia: a retrospective survey. Blood. 2008;111(2):666-71.
26. Landolfi R, Marchioli R, Kutti J, et al. Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med. 2004;350(2):114-24.
27. CHIEVITZ E, THIEDE T. Complications and causes of death in polycythaemia vera. Acta Med Scand. 1962;172:513-23.
28. Khanal N, Giri S, Upadhyay S, Shostrom VK, Pathak R, Bhatt VR. Risk of second primary malignancies and survival of adult patients with polycythemia vera: A United States population-based retrospective study. Leuk Lymphoma. 2016;57(1):129-33.
29. Ruggeri M, Gisslinger H, Tosetto A, et al. Factor V Leiden mutation carriership and venous thromboembolism in polycythemia vera and essential thrombocythemia. Am J Hematol. 2002;71(1):1-6.